Animal studies could lead to blood tests that could guide doctors in better matching drugs to patients based on immune system ...

Axsome Therapeutics said on Tuesday it will narrow the focus of a late-stage study of its depression drug after an initial run of the trial showed improvement only in a small subgroup of patients.

(Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced in addition to developing TH104 for the proposed ...

“Every person working on it was let go,” Hoenig said, noting that the data collection is mandated by Congress. The office is ...

Elon Musk reveals he uses prescribed ketamine biweekly to manage depression, stressing its controlled use to maintain mental ...

The evidence-backed model delivered impressive results, but it doesn’t validate the wave of AI therapy bots flooding the ...

Too few people get diagnosed and treated for postpartum depression. But a blood test could change that Postpartum depression ...

A NYC dermatologist is now offering brain treatments with an Exomind device, which is said to be a high-tech fix for ...

Lipocine has announced the commencement of a Phase III clinical trial of LPCN 1154, being developed for postpartum depression ...

Policy update increases access for millions covered by Evernorth Health ServicesMALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial ...

Advancing CMC plan to meet requirements of a New Drug Application BRIDGEWATER ... Prophylaxis of Respiratory and/or Nervous System Depression in Military Personnel and Chemical Incident Responders ...

A depression drug candidate that’s a key part of Johnson & Johnson’s neuroscience strategy has failed a Phase 3 clinical trial, the latest dose of disappointing news for an emerging class of ...